Pharma Capital

Summit Therapeutics boss to speak at DMD conference

CEO Glyn Edwards is to participate in a DMD pipeline panel discussion at the JMP Securities Life Sciences Conference
DMD
DMD is a wasting disease that primarily affects boys and young men

Glyn Edwards, chief executive officer of Summit Therapeutics PLC (LON:SUMM, NASDAQ:SMMT), is to speak at a New York life sciences conference this month.

The boss of the dual-listed drug discovery and development company, which is focused on advancing therapies for Duchenne muscular dystrophy (DMD) and Clostridium difficile infection, will participate in a DMD pipeline panel discussion at the JMP Securities Life Sciences Conference on 21 June 2017.

Edwards will also participate in one-to-one meetings at the conference. 

John-H.jpg
Why Invest In Summit Therapeutics PLC? Read More Here

Register here to be notified of future SUMM Company articles
View full SUMM profile

Summit Therapeutics PLC Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.